SCHEMBL353070

SCHEMBL353070

C=CCC(Cc1ccccc1)N=C=S

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
MIF P14174 8/20 0.39
TRPA1 O75762 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP2E1 P05181 1/20 0.37
CYP2A6 P11509 1/20 0.37
HIF1A Q16665 1/20 0.37
CYP2A13 Q16696 1/20 0.37
EPAS1 Q99814 1/20 0.37
EPHX1 P07099 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.34
NAAA Q02083 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957097 0.75 MIF (0.55) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL8762408 0.69 MIF (0.52) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL19899208 0.69 SMN1; SMN2 (0.46) SMN1; SMN2ATML3MBTL1CYP2A6EPHX1
SCHEMBL19899196 0.69 SMN1; SMN2 (0.46) SMN1; SMN2ATML3MBTL1CYP2A6EPHX1
SCHEMBL6386364 0.68 MIF (0.65) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL2369596 0.67 TRPA1 (0.44) SMN1; SMN2TRPA1ATML3MBTL1EPHX1
SCHEMBL3257633 0.67 SMN1; SMN2 (0.44) SMN1; SMN2ATML3MBTL1CYP2A6EPHX1
SCHEMBL1071466 0.67 TAAR1 (0.48) SMN1; SMN2TRPA1CYP2A6EPHX1
SCHEMBL10901103 0.67 SMN1; SMN2 (0.44) SMN1; SMN2ATML3MBTL1CYP2A6EPHX1
SCHEMBL5159235 0.67 EPHX1 (0.46) SMN1; SMN2ATML3MBTL1CYP2A6EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060020299-A1 Methods and systems for management of alzheimer's disease BRAINSGATE LTD. (IL) 2006-01-26 US claimed
US-20050266099-A1 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head BRAINSGATE LTD. (IL) 2005-12-01 US claimed
EP-1521614-A2 METHODS AND SYSTEMS FOR MANAGEMENT OF ALZHEIMER'S DISEASE Brainsgate Ltd. (IL) 2005-04-13 EP claimed
EP-1503734-A2 METHODS AND APPARATUS FOR MODIFYING PROPERTIES OF THE BBB AND CEREBRAL CIRCULATION BY USING THE NEUROEXCITATORY AND/OR NEUROINHIBITORY EFFECTS OF ODORANTS ON NERVES IN THE HEAD Brainsgate Ltd. (IL) 2005-02-09 EP claimed
WO-2003105658-A2 METHODS AND SYSTEMS FOR MANAGEMENT OF ALZHEIMER'S DISEASE BRAINSGATE LTD. (IL) 2003-12-24 WO claimed
WO-2003090599-A2 METHODS AND APPARATUS FOR MODIFYING PROPERTIES OF THE BBB AND CEREBRAL CIRCULATION BY USING THE NEUROEXCITATORY AND/OR NEUROINHIBITORY EFFECTS OF ODORANTS ON NERVES IN THE HEAD BRAINSGATE LTD. (IL) 2003-11-06 WO claimed
US-9233245-B2 SPG stimulation BRAINSGATE LTD. (IL) 2016-01-12 US disclosed
US-20150174406-A1 SPG STIMULATION BRAINSGATE LTD. (IL) 2015-06-25 US disclosed
US-8958881-B2 Neuroprotective electrical stimulation BRAINSGATE LTD. (IL) 2015-02-17 US disclosed
US-8954149-B2 External stimulation of the SPG BRAINSGATE LTD. (IL) 2015-02-10 US disclosed
US-20130218249-A1 NEUROPROTECTIVE ELECTRICAL STIMULATION BRAINSGATE LTD. (IL) 2013-08-22 US disclosed
US-8406869-B2 Post-acute electrical stimulation treatment of adverse cerebrovascular events BRAINSGATE, LTD. (IL) 2013-03-26 US disclosed
US-20120016434-A1 POST-ACUTE ELECTRICAL STIMULATION TREATMENT OF ADVERSE CEREBROVASCULAR EVENTS BRAINSGATE LTD. (IL) 2012-01-19 US disclosed
WO-2004043217-A2 STIMULATION FOR TREATING EYE PATHOLOGIES BRAINSGATE LTD. (IL) 2004-05-27 WO disclosed
WO-2004045242-A2 STIMULATION FOR TREATING EAR PATHOLOGIES BRAINSGATE LTD. (IL) 2004-05-27 WO disclosed
WO-2004010923-A2 DELIVERING COMPOUNDS TO THE BRAIN BY MODIFYING PROPERTIES OF THE BBB AND CEREBRAL CIRCULATION BRAINSGATE LTD. (IL) 2004-02-05 WO disclosed
WO-2003105658-A2 METHODS AND SYSTEMS FOR MANAGEMENT OF ALZHEIMER'S DISEASE BRAINSGATE LTD. (IL) 2003-12-24 WO disclosed
WO-2003090599-A2 METHODS AND APPARATUS FOR MODIFYING PROPERTIES OF THE BBB AND CEREBRAL CIRCULATION BY USING THE NEUROEXCITATORY AND/OR NEUROINHIBITORY EFFECTS OF ODORANTS ON NERVES IN THE HEAD BRAINSGATE LTD. (IL) 2003-11-06 WO disclosed
US-20030176898-A1 Stimulation for treating eye pathologies BRAINSGATE LTD. (IL) 2003-09-18 US disclosed
US-20030176892-A1 Administration of anti-inflammatory drugs into the central nervous system BRAINSGATE, LTD. (IL) 2003-09-18 US disclosed